A more compelling rationale for switching medications—particularly in light of “marginal” cost savings provided by biosimilars in the United States—is necessary, says the guideline.
The American College of Rheumatology, the Spondylitis Association of America, and the Spondyloarthritis Research and Treatment Network, have released an updated treatment guideline for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. In the guideline, the organizations strongly recommend that patients who are stable on their therapy not be made to switch to a biosimilar of their anti—tumor necrosis factor (anti-TNF) therapies.
The guideline update, write the authors, which analyzed 26 new clinical questions since the previous guideline was issued in 2015, was primarily motivated by the availability of new treatment options, including biosimilars, and to answer questions among both patients and providers as to how these new products fit within the pharmacologic treatment strategy.
“While the efficacy of originator and biosimilar…is comparable, and although either could be chosen to initiate new courses of [anti-TNF] treatment, it was the opinion of the panel to recommend against mandated switching to a biosimilar during the course of treatment, in the absence of evidence of interchangeability,” write the guideline’s authors. They add that medication changes can increase the risk of destabilizing a patient’s condition, and that a more compelling rationale for switching medications—particularly in light of “marginal” cost savings provided by biosimilar anti-TNFs in the United States—is necessary.
In addition to its recommendation against mandatory switching, the guideline also strongly recommends against switching to a biosimilar of the first anti-TNF treatment in patients whose disease is still active despite anti-TNF treatment, as response to a biosimilar can be expected to be the same as response to an originator.
For patients who have primary nonresponse to a first anti-TNF agent, the guideline conditionally recommends treatment with secukinumab or ixekizumab rather than cycling to a different anti-TNF. However, for patients with secondary nonresponse to anti-TNF, the guideline recommends cycling to a different anti-TNF agent rather than switching to a biologic with a different mechanism of action. These recommendations diverge from the 2015 guideline, which conditionally recommended a trial of a second anti-TNF for cases of nonresponse, whether primary or secondary.
The guideline also recommends that, in patients for whom nonsteroidal anti-inflammatory drugs have not been adequate, anti-TNF agents are recommended, though no particular anti-TNF agent is the preferred choice; treatment decisions should take into account patient preferences regarding frequency and route of administration.
Anti-TNFs are recommended over secukinumab or tofacitinib, and the guideline strongly recommends against systemic glucocorticoid use.
Discontinuing or tapering biologics in stable patients is not recommended, and if tapering is being considered, patients should be counseled about their risk for increased disease activity. Treat-to-target strategies are also not recommended.
Finally, concomitant low-dose methotrexate in patients whose disease is either active or stable under anti-TNF therapy is not recommended.
Reference
Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [published online August 22, 2019]. Arthritis Care Res. doi: 10.1002/acr.24025.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.